000 02102nam  2200337za 4500
0019.833635
003CaOODSP
00520221107150247
007cr |||||||||||
008170310s2017    onc    #ob   f000 0 eng d
020 |a978-0-660-07912-7
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-176/2017E-PDF
24500|aNACI literature review for HPV immunization of immunocompromised populations |h[electronic resource].
2461 |iAt head of title: |aAdvisory Committee review, National Advisory Committee on Immunization (NACI)
260 |aOttawa : |bPublic Health Agency of Canada, |c2017.
300 |a60 p.
500 |aTitle from cover.
500 |aIssued also in HTML format.
500 |aIssued also in French under title: Examen de la documentation du CCNI concernant l'immunisation contre le VPH des populations immunodéprimées.
504 |aIncludes bibliographical references.
520 |a"Immunocompromised populations are at increased risk for HPV infection and for developing HPV-associated cancers. However, additional clarity is required surrounding the immunogenicity and safety outcomes of HPV immunization for immunocompromised populations. To address this information gap, a research question was developed by the National Advisory Committee on Immunization (NACI) human papillomavirus (HPV) Working Group and used to guide a literature review"--Executive Summary, p. 5.
69207|2gccst|aImmunization
69207|2gccst|aInfectious diseases
69207|2gccst|aResearch
7102 |aPublic Health Agency of Canada. |bInfectious Disease Prevention and Control Branch.
77508|tExamen de la documentation du CCNI concernant l’immunisation contre le VPH des populations immunodéprimées |w(CaOODSP)9.833636
85640|qPDF|s1.21 MB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-176-2017-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/healthy-living/literature-review-human-papillomavirus-immunization-immunocompromised-populations.html